597121HCD Economics, Daresbury, UK.
Centre for Haematology, Department of Immunology and Inflammation, 216773Imperial College London, London, UK.
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221120583. doi: 10.1177/10760296221120583.
Von Willebrand disease (VWD) is one of the most common inherited bleeding disorders, imposing a substantial health impact and financial burden. The ost of on Willebrand disease in urope: A ocioeconomic tudy (CVESS) characterises the socio-economic cost of VWD across Germany, Spain, Italy, France, and the UK.
A retrospective, cross-sectional design captured 12 months of patient disease management, collected from August-December 2018, for 974 patients. This enabled estimation of direct medical, direct non-medical and indirect costs, utilising prevalence estimates to extrapolate to population level.
Total annual direct medical cost (including/excluding von Willebrand factor [VWF]) across all countries was the highest cost (€2 845 510 345/€444 446 023), followed by indirect costs (€367 330 271) and direct non-medical costs (€60 223 234). Differences were seen between countries: the UK had the highest direct medical costs excluding VWF (€159 791 064), Italy the highest direct-non medical (€26 564 496), and Germany the highest indirect cost burden (€197 036 052). Total direct medical costs per adult patient increased across VWD types with Type 1 having the lowest cost (€23 287) and Type 3 having the highest cost (€133 518).
A substantial financial burden arises from the prevalence of VWD for the European healthcare systems considered.
血管性血友病（VWD）是最常见的遗传性出血性疾病之一，对健康和经济造成重大影响。欧洲血管性血友病的成本：一项社会经济学研究（CVESS）描述了德国、西班牙、意大利、法国和英国的 VWD 社会经济成本。
回顾性、横断面设计，对 974 例患者的 12 个月疾病管理数据进行了收集，时间为 2018 年 8 月至 12 月。这使我们能够利用患病率估计值估算直接医疗、直接非医疗和间接成本。
所有国家的年直接医疗总费用（包括/不包括血管性血友病因子[VWF]）均为最高成本（€2845510345/€444446023），其次是间接成本（€367330271）和直接非医疗成本（€60223234）。各国之间存在差异：英国不包括 VWF 的直接医疗费用最高（€159791064），意大利的直接非医疗费用最高（€26564496），德国的间接成本负担最高（€197036052）。每种 VWD 类型的成年患者的直接医疗总费用均随类型增加而增加，其中 1 型的成本最低（€23287），3 型的成本最高（€133518）。
考虑到所考虑的欧洲医疗保健系统中 VWD 的流行程度，存在着巨大的经济负担。
